Filing Flows › Health Care › Lftd Partners (LIFD)
Lftd Partners (LIFD) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Lftd Partners (LIFD) Q2 2026 earnings results →
Q2 2026 Revenue down 16% year over year to $8.7M · 17¢ of every $1 of revenue lost · operating margin -17.5%
Lftd Partners made $8.7M in Q2 2026 (-16% Y/Y): Products to Distributors $6.1M, Products to End Consumers $1.2M, Products to Wholesalers $962K. Operating margin -17.5%, net loss $1.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $8.7M in Q2 2026, down 16% year over year and down 5% from the previous quarter. Products to Distributors was the largest line at 70% of revenue. Products to Distributors lost $1.3M year over year (down 17%), 80% of the total change.
Gross margin was 7.5%, down 24.0 points from Q2 2025. Operating costs exceeded revenue by $1.5M, an operating margin of -17.5%. Operating expenses fell 35% while revenue fell 16%. The quarter ended with a net loss of $1.4M, narrower than the previous quarter's $4.2M loss.
Operating cash flow was −$555K. Non-cash charges added back $116K of depreciation and amortization. Working capital and other items added $768K. Capital expenditures of $19K exceeded it, leaving free cash flow of −$574K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $8.7M | -16% | -17.5% | −$1.4M | −$555K |
| Q1 2026 | 10-Q | May 15, 2026 | $9.2M | +0.4% | -49.8% | −$4.2M | $459K |
| Q4 2025 | 10-K | Apr 1, 2026 | $8.4M | -0.8% | 0.5% | −$24.9M | $536K |
| Q3 2025 | 10-Q | Nov 14, 2025 | $9.1M | +4% | 14.5% | $634K | $699K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $10.3M | +9% | -1.1% | −$269K | −$266K |
| Q1 2025 | 10-Q | May 15, 2025 | $9.1M | -14% | -3.6% | −$303K | $352K |
| Q4 2024 | 10-K | Mar 31, 2025 | $8.5M | -37% | 0.9% | $1K | −$893K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Lftd Partners
On February 24, 2020, the Company acquired 100% of the ownership interests of Lifted. All of the Company’s sales are generated by the Company’s wholly owned subsidiary Lifted; LFTD Partners by itself generates no sales. We also do not recognize any revenue or earnings from our investments in Bendistillery and Ablis. LFTD Partners’ other wholly owned subsidiary, Highlandia Inc., does not generate any sales. The Company's cash needs for working capital, capital expenditures, growth opportunities, the payments of Series A and Series B Preferred Stock dividends, bonuses, its financial obligations under its loan agreements with Surety Bank, and other obligations, are expected to be met with current cash on hand and cash flows provided by operating activities.
In its own words, from its 10-K, filed Apr 1, 2026.
Lftd Partners against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -16% against the peers' median +7%. Operating margin: -17.5% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| LIFD Lftd Partners | Q2 2026 | $8.7M | -16% | -17.5% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Lftd Partners 10-Q on SEC EDGAR · CIK 1391135 · Pharmaceutical Preparations
More on LIFD
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results